EZH2 and myeloid neoplasm: Homozygous inactivating EZH2 mutations were detected in a portion of myeloid malignancies [14], [15], raising the possibility that EZH2 may either exert pro- or anti-oncogenic activities, in a cell type-dependent manner [16].